Joint Technology. The Parties agree that, in order to effectuate the provisions of Section 4.4.2, subject to any exclusive licenses granted hereunder, (a) the non-use provisions of this Article 9 shall not apply to each Party’s use of Joint Technology, and (b) each Party may disclose the Joint Technology to Third Parties who are under terms of confidentiality no less strict than those contained in this Agreement.
Joint Technology. The Parties acknowledge and agree that the Parties will each own an equal, undivided interest in Joint Technology. Each Party will have the right to Exploit the Joint Technology without a duty of seeking consent of or accounting to the other Party; provided, that neither Party will have the right to disclose (except as provided in Section 7) or license (except as may be permitted under Section 3) any Joint Technology without the prior written consent of the other Party.
Joint Technology. The term “Joint Technology” shall mean any Technology made or developed jointly by at least one employee or consultant of Sponsor (it being understood that, for purposes of this paragraph, no TSRI employee shall be considered a consultant of Sponsor) and at least one employee of TSRI, as determined under principles of inventorship under US patent law.
Joint Technology. Each Party hereby grants the other Party a world-wide, non-exclusive, perpetual, royalty-free, fully paid up, freely sublicenseable right and license under its interest in the Joint Technology to exploit compounds that are not guanylate cyclase C agonists anywhere in the world, without compensating or accounting to the other Party.
Joint Technology. The parties hereby agree that in the event that the disclosed Technology is Joint Technology and Sponsor neither exercises its Option to such Joint Technology nor has a license to such Joint Technology under the Exclusive License Agreement (i.e., if the Exclusive License Agreement has terminated), both Parties shall (i) have no further obligations to each other with respect to such Joint Technology and any resulting Patent Rights; and (ii) be free to independently license or otherwise dispose of their rights to such Joint Technology and any resulting Patent Rights on a worldwide basis without accounting to the other Party.
Joint Technology. Subject to the terms and conditions of this Agreement (including Sections 2.2 and 2.3), each Party hereby grants the other Party a worldwide, irrevocable, non-exclusive, perpetual, royalty-free, fully paid up, freely sublicensable right and license to exploit the Joint Technology in any manner without compensating or accounting to the other Party.
Joint Technology. The Parties shall own jointly any and all Information, including Data, discovered, generated, created or made jointly by two or more individual inventors with at least one individual inventor being an employee or consultant to each of the Parties and/or its respective Affiliates and/or their respective approved subcontractors in the course of performing or exercising the Parties’ rights under this Agreement, together with all Patents and other intellectual property rights in any such jointly made Information, but excluding the Aptose Program Technology (collectively, the “Joint Technology”). Each Party may exercise its ownership rights in and to such Joint Technology, including the right to license or otherwise to exploit, transfer or encumber its ownership interest, without an accounting or obligation to, or consent required from, the other Party, but subject to the obligations under this Agreement and any licenses granted under or in accordance with this Agreement.
Joint Technology. (a) VARIAGENICS shall have sole and exclusive ownership of all Technology relating to NuCleave-TM- Reagents or NuCleave-TM- Technology jointly invented in the Alliance Program by both VARIAGENICS (and/or any party performing sponsored research for VARIAGENICS) and WATERS (and/or any party performing sponsored research for WATERS) or invented in the Alliance Program by one party (or during any research sponsored by such party) with the use of or based upon the Technology of the other party (collectively, the "Joint NuCleave-TM- Technology"), and shall exclusively own all Joint Patent Rights with respect to Joint NuCleave-TM- Technology, subject to license rights held by WATERS with respect to Licensed Products.
Joint Technology. As between the Parties, all rights, title and interest in and to the Joint Technology shall be owned jointly by Ramot and the Company.
Joint Technology. If, during the Collaboration Period, one or more employees or consultants of Aurora,
